Description
Abiraterone Acetate, marketed under the brand name ZYTIGA, It is an prescription medication that has been approved abiraterone acetate for several uses, including:
Metastatic castration-resistant prostate cancer (CRPC): The FDA approved abiraterone acetate in 2011.
Metastatic high-risk castration-sensitive prostate cancer (CSPC): The FDA approved abiraterone acetate in combination with prednisone in 2018.
Fine-particle formulation: The FDA approved a fine-particle formulation of abiraterone acetate (Yonsa) in 2018. Yonsa is used in combination with methylprednisolone to treat patients with CRPC.
What is Zytiga (Abiraterone Acetate) ?
ZYTIGA is a CYP17 inhibitor indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer. The recommended dose of ZYTIGA is 1,000 mg (four 250 mg tablets) administered orally once daily in combination with prednisone 5 mg administered orally twice daily.
ZYTIGA is a prescription medicine that is used along with prednisone. ZYTIGA is used to treat men with castration-resistant prostate cancer (prostate cancer that is resistant to medical or surgical treatments that lower testosterone) that has spread to other parts of the body. ZYTIGA is not for use in women.
How to order approved “Zytiga (Abiraterone Acetate) for Tablet” Medicine?
ZYTIGA (Abiraterone Acetate) Tablets is a prescription medicine, it can be accessed through the Named Patient Program (NPP) for treatment in the following city of India – Bengaluru, Delhi, Chennai, Hyderabad, Mumbai, Pune, Kolkata, Ahmedabad, Gurgaon. To inquire about the cost price of purchasing ZYTIGA and arranging delivery to your location, please get in touch with Mr. Rakesh at +91 9910645395 or send an enquiry to info@cancermedicinesnetwork. We assure you of the quality of the product and guarantee delivery in accordance with your specific requirements.